Ligesom for andre lægemidler, der påvirker renin- angiotensinsystemet, gælder det, at sorte hypertensionspatienter responderer betydeligt dårligere på irbesartanmonoterapi.
As is the case with other medicinal products that affect the renin-angiotensin system, black hypertensive patients have notably less response to irbesartan monotherapy.